Mitapivat for phosphofructokinase deficiency.
Al-Samkari H.
Am J Hematol. 2024 Oct;99(10):2045-2046. doi: 10.1002/ajh.27442. Epub 2024 Jul 23.
Phosphofructokinase deficiency; past, present and future.
Nakajima H, Raben N, Hamaguchi T, Yamasaki T.
Curr Mol Med. 2002 Mar;2(2):197-212. doi: 10.2174/1566524024605734.
Phosphofructokinase deficiency: recent advances in molecular biology.
Nakajima H, Hamaguchi T, Yamasaki T, Tarui S.
Muscle Nerve Suppl. 1995;3:S28-34. doi: 10.1002/mus.880181408.
The glycolytic enzyme PFKFB3 drives kidney fibrosis through promoting histone lactylation-mediated NF-κB family activation.
Wang Y, Li H, Jiang S, Fu D, Lu X, Lu M, Li Y, Luo D, Wu K, Xu Y, Li G, Zhou Y, Zhou Y, Chen W, Liu Q, Mao H.
Kidney Int. 2024 Aug;106(2):226-240. doi: 10.1016/j.kint.2024.04.016. Epub 2024 May 22.
Glycogen Storage Disease.
Stone WL, John TA, Anastasopoulou C, Basit H, Adil A.
2025 Jan 21. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.
No effect of triheptanoin in patients with phosphofructokinase deficiency.
Raaschou-Pedersen DE, Madsen KL, Løkken N, Storgaard JH, Quinlivan R, Laforêt P, Lund A, Van Hall G, Vissing J, Ørngreen M.
Neuromuscul Disord. 2022 Apr;32(4):295-304. doi: 10.1016/j.nmd.2022.01.012. Epub 2022 Feb 4.
Role of PFKFB3-driven glycolysis in vessel sprouting.
De Bock K, Georgiadou M, Schoors S, Kuchnio A, Wong BW, Cantelmo AR, Quaegebeur A, Ghesquière B, Cauwenberghs S, Eelen G, Phng LK, Betz I, Tembuyser B, Brepoels K, Welti J, Geudens I, Segura I, Cruys B, Bifari F, Decimo I, Blanco R, Wyns S, Vangindertael J, Rocha S, Collins RT, Munck S, Daelemans D, Imamura H, Devlieger R, Rider M, Van Veldhoven PP, Schuit F, Bartrons R, Hofkens J, Fraisl P, Telang S, Deberardinis RJ, Schoonjans L, Vinckier S, Chesney J, Gerhardt H, Dewerchin M, Carmeliet P.
Cell. 2013 Aug 1;154(3):651-63. doi: 10.1016/j.cell.2013.06.037.
Infantile form of muscle phosphofructokinase deficiency in a premature neonate.
Wu PL, Yang YN, Tey SL, Yang CH, Yang SN, Lin CS.
Pediatr Int. 2015 Aug;57(4):746-9. doi: 10.1111/ped.12616. Epub 2015 Jun 25.
p53-responsive CMBL reprograms glucose metabolism and suppresses cancer development by destabilizing phosphofructokinase PFKP.
Huang Y, Xiong C, Wang C, Deng J, Zuo Z, Wu H, Xiong J, Wu X, Lu H, Hao Q, Zhou X.
Cell Rep. 2023 Nov 28;42(11):113426. doi: 10.1016/j.celrep.2023.113426. Epub 2023 Nov 16.
Muscle phosphofructokinase deficiency.
Massa R, Sancesario G, Bernardi G.
Neurology. 1997 Sep;49(3):899. doi: 10.1212/wnl.49.3.899.
